Vaxcyte

As the summer comes to a close, we want to give a huge thanks to all of our 2024 summer interns for their hard work, dedication and enthusiasm these past few months! Our interns have been working at our San Carlos headquarters across various departments including finance, facilities, protein development, supply chain, CMC and immunoassay. We’re passionate about developing the next generation of biotech leaders and giving students an opportunity to gain valuable hands-on work experience to complement their college curriculum. #biotech #interns [From left to right: Avery Tuthill, Rachna Balasubramanian Maya Narang Vijini Liyanage, Surabhi Pandey and Donovan Pareja-jimenez (not pictured: Katherine Brenner).]

We are pleased to share that the VAX-24 Phase 2 study in adults aged 65 and older has been published in the medical journal Vaccine. The publication of these positive results is a testament to the potential of VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), as well as our cell-free technology in developing carrier-sparing vaccines. Our PCV candidates, VAX-24 and VAX-31, our 31-valent PCV, are designed to deliver the broadest-spectrum of coverage to protect against invasive pneumococcal disease (IPD) in adults and infants while maintaining coverage of the historically circulating strains. Congratulations to the authors of this important publication. https://lnkd.in/dzNssgYU

Pipetting - the Olympic sport you’ve never heard of. In honor of the Summer Olympics, we recently hosted our first-ever Pipette Olympics during which our talented team members competed in three group-based events — the pipette tip toss, pipette painting and pipette relay. The competition was fierce, leading to a speed pipetting tiebreaker. Congratulations to our gold medalist, early-stage Analytical Development/Conjugation team, who took pipetting to a whole new level! Shoutout to our silver and bronze medalists on the Analytical and Drug Product teams. Thank you to everyone who participated and made this event unforgettable! #culture #team #pipette #olympics #summerolympics

We are pleased to share our second quarter 2024 business and financial update as we continue to make significant strides in advancing our pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. We look forward to sharing VAX-31 adult Phase 1/2 study topline data in September, which will provide significant insights into the full potential of this vaccine candidate across the adult population.   Additionally, we expect to share VAX-24 infant Phase 2 study topline data by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025. We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market today.   Read more here: https://lnkd.in/g7J7ywWm #biotechnology #vaccines #publichealth

Annette Makarewycz, Vaxcyte's Vice President of Talent Acquisition, reflects on her decision to join our team earlier this year, and what makes our company unique. This includes celebrating Vaxcyte being recognized by Great Place to Work as the # 1 ranked biotech on the Best Small and Medium Workplaces in the Bay Area list. Learn more below and explore our current job listings: vaxcyte.com/job-listings/ #hiring #biotech #vaccines #culture

We are thrilled to share that we have been recognized by Great Place to Work as one of the Best Small and Medium Workplaces in the Bay Area for the second year in a row! This year, we are #11 overall and the #1-ranked biotech in our category. At Vaxcyte, we lead with heart to achieve bold goals and are grateful to the entire team for making this company such a special place to work. Check out our Great Place to Work page: https://lnkd.in/gxPHBaSb    Interested in joining our growing team? Learn more at vaxcyte.com/job-listings/ #GreatPlacetoWork #culture #biotech

Vaxcyte’s cell-free protein synthesis platform enables us to overcome limitations of traditional chemistry and develop potentially superior and novel vaccine candidates. With this unique technology, we are advancing our broad-spectrum pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31, that are designed to prevent invasive pneumococcal disease, as well as vaccines to potentially address bacterial diseases like Group A Strep and Shigella for which there are no preventative treatments.   Vaxcyte's Chief Executive Officer and Co-Founder Grant Pickering and Vice President of Research and Co-Founder Jeff Fairman share more about our platform, as well as our team's chemistry, which fuels our collaborative culture and drives our innovation. Learn more at vaxcyte.com/approach  #VaccineInnovation #vaccines #culture 

At Vaxcyte, we value moments that bring us together. Last week, our team members took a break from work to participate in and cheer on their colleagues during our first-ever Vaxcyte Cornhole Tournament. It was a fantastic afternoon filled with good weather, great company and lots of fun and bullseyes! Congratulations to our cornhole champions JD Aurellano and Harsha Lakshmankumar and a special shoutout to Itzel Garcia-Ocampo who won best form! #culture #biotech 

We’re excited to honor Mark Iverson, Senior Staff Scientist, Protein, who received Vaxcyte’s Powering Beyond Legacy Award. This award honors an individual who consistently models all four of our Vaxcyte core values over a significant period, leaving a meaningful impact. Throughout his seven years at Vaxcyte, Mark has constantly demonstrated the values of Aim High, Lead with Heart, Rethink Convention and Model Excellence. Beyond the lab, Mark has also been an active member of our culture club for years, helping to create opportunities for Vaxcyte team members to connect. Thank you, Mark, for your dedication to supporting Vaxcyte’s mission, culture and team!  

We are pleased to share our first quarter 2024 business and financial update as we continue to make meaningful progress across our business, particularly in advancing our pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31, which are intended to deliver the broadest-spectrum of coverage against invasive pneumococcal disease. We look forward to sharing the expected VAX-31 adult Phase 1/2 study topline data in the third quarter of this year and our first VAX-24 infant Phase 2 study topline data by the end of the first quarter of 2025. Together, these milestones will provide significant insight into our PCV franchise’s ability to achieve its full potential across the adult and pediatric populations. Read more here: https://lnkd.in/gjrrD6VY #biotechnology #vaccines #publichealth